Gossamer Bio Inc
Closed
SectorHealthcare
10.61 7,478.57
Overview
Share price change
24h
Min
10.46
Max
10.74
Income | 64M 17M |
|---|---|
Sales | -7.7M 9.2M |
EPS | -0.2 |
Profit margin | 182.94 |
Employees | 161 |
EBITDA | -28M -71M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -90.03% downside |
Market Cap | -391K 86M |
|---|---|
Previous open | -7467.96 |
Previous close | 10.61 |
News Sentiment
By Acuity
79%
21%
314 / 339 Healthcare
Gossamer Bio Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Gossamer Bio Inc Forecast
Price Target
By TipRanks
-90.03% downside
12 Months Forecast
Average 1.07 USD -90.03%
High 2 USD
Low 0.28 USD
Based on 5 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.
Sentiment
By Acuity
314 / 339 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
$
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.